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Abstract
The Food and Drug Administration (FDA) of the USA is charged with protecting the American public from products that are
adulterated, misbranded or which fit the federal definition of ‘health fraud.’ One company, the Standard Homeopathic
Company and its Hyland’s line of homeopathic remedies, has violated all three of these laws. Hyland’s Teething Tablets have
injured babies through toxic amounts of belladonna, and it makes numerous unsupported medical claims for nonprescription products that violate misbranding laws. Further, since the products lack any evidence of safety and efficacy, they
fit the FDA definition of ‘health fraud.’ The FDA has attempted to force Standard Homeopathic to follow the relevant laws,
but the company has not so far fully corrected the illegal acts.
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Introduction
The Food and Drug Administration (FDA) agency of
the USA has many responsibilities assigned to it
based on the Food, Drug and Cosmetic Act (FDCA) of
1938, subsequent amendments, and additional legislative acts. One of the overarching responsibilities of
the FDA is to protect the public’s health by assuring
safety and efficacy of medications and ensuring accuracy in the manufacture and labelling of the nation’s
drug supply. The passage of the FDCA was hastened
by the legal marketing of a toxic elixir that killed
107 people, including many children. The FDCA
demanded evidence of safety for new drugs and the
resulting Kefauver–Harris Amendments of 1962
further strengthened the rules for drug safety, including the requirement that manufacturers prove the
effectiveness of their drugs.
The definition of ‘drug’
Because the primary enforcement of the FDCA is
vested in the FDA, critical components of the FDCA
law must be understood to allow citizens to grasp

why the FDA acts in the manner it does. The FDCA1
provides the definition critical to understanding
what is considered a drug and, thus, what is subject
to FDA oversight:
‘The term “drug” means (A) articles recognized in the
official United States Pharmacopeia, official Homeopathic Pharmacopeia of the United States, or official
National Formulary, or any supplement to any of
them; and (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of
disease in man or other animals; and (C) articles
(other than food) intended to affect the structure or
any function of the body of man or other animals;
and (D) articles intended for use as a component of
any articles specified in clause (A), (B), or (C).’
If the FDA determines that a product meets the definition of ‘drug’, the FDA can adjudicate the article to
be a drug and is viewed as having authority over its
regulation. As a result, if the FDA determines that the
product is a drug, it can be legally involved
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in the oversight of manufacturing and the accurate
labelling of that product.

Health fraud

Prohibited acts: adulteration
and misbranding

‘The deceptive promotion, advertisement, distribution or sale of articles, intended for human or animal
use, that are represented as being effective to diagnose, prevent, cure, treat, or mitigate disease (or other
conditions), or provide a beneficial effect on health,
but which have not been scientifically proven safe
and effective for such purposes. Such practices may
be deliberate, or done without adequate knowledge
or understanding of the article.’8

The FDA has authority to enforce the FDCA in a
variety of ways. This enforcement is premised on the
FDCA, which provides, in part, the following prohibited acts:
(a) The introduction or delivery for introduction
into interstate commerce of any food, drug,
device or cosmetic that is adulterated or
misbranded.
(b) The adulteration or misbranding of any food,
drug, device or cosmetic in interstate
commerce.2
The concept of adulteration deals primarily with
manufacturers and is intended to regulate the facility
and the means of production rather the products
themselves. This area involves the drug’s strength,
purity and quality, as well as the requirements to
comply with Current Good Manufacturing Practice
(CGMP) regulations. Non-compliance with the
CGMP can result in litigation against the company
and a declaration that its drugs are adulterated.
The concept of misbranding focuses on representations made by the manufacturer on the label or labelling. The provisions under the FDCA §502 deem a
product to be misbranded ‘if its labeling is false or
misleading in any particular.’3 The FDA has extensive
regulations dealing with the proper labelling requirements of drug products, both prescription and overthe-counter.4,5
Violations of the FDCA are considered strict liability offences. This means that regardless of the individual’s intentions or knowledge, guilt can be assessed.
However, this requires prosecution, is time consuming and demands enormous resources. The FDA has
other tools that it can utilise to correct violations.
Under a new 2007 law, the FDA has authority to order
a recall of products.6 Alternatively, the manufacturer
may initiate a product recall without FDA involvement. While injunctive relief is an option, it must be
shown that irreparable harm will result if the actions
to cease and desist is proved, and sometimes this can
be difficult. The FDA can seize any adulterated or
misbranded drug. Seizing product at the manufacturer’s site may be easy, but trying to do this at over
60 000 pharmacies would be labour intensive. In
some instances, violations may not appear to require
prosecution or seizure, and in those cases Congress,
under §309, created a system whereby the FDA can
issue warning letters to violators as a first step in
correcting apparent violations.7

Another area of concern that the FDA deals with is
that of health fraud. Health fraud is defined as:

Should such products exist and pose a direct health
hazard, the FDA has stated that it will assign them
their highest priority. Health-fraud products for
which there is not a documented direct health threat
will still be considered for regulatory action but on a
lower priority.
Homeopathic products
One area of focus for the FDA in addressing misbranding, adulteration and fraud is that of the manufacture and promotion of homeopathic products.
Until recently, homeopathic drugs have been marketed on a limited scale by a few manufacturers who
have been in business for many years and have
predominately served the needs of a small number of
practitioners. Historically, homeopathic products
have borne little or no labelling for the consumer
and were therefore free of violations under the
misbranding provisions of the FDCA. However,
today the homeopathic drug market has become a
multimillion-dollar industry in the USA and is under
greater scrutiny by the FDA.
Homeopathic products generally must meet the
standards for strength, quality and purity set forth in
the US Homeopathic Pharmacopeia.9 Even if these
requirements are met, these products still must be
shown to be safe, effective and not misbranded for
their intended uses and they must comply with drug
product labelling requirements of the FDCA. One
aspect of labelling is that, if a product is intended for
purchase by a consumer, it must be labelled in such a
manner that it has ‘adequate directions for use’.3 If
such labelling cannot be provided, the drug product
will be considered a prescription item.
Questions about homeopathy and
its usefulness
While homeopathic products may be approved
as drugs in the USA, many individuals still question
the usefulness of such products. Followers of
homeopathy believe in the practice of diluting a
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product to the point that not a single molecule
remains, and basing the purported therapeutic
response on the fact that the water ‘will remember’
that the drug was there.
In the 1800s, homeopathy was viewed somewhat
positively in the USA. In the case of People ex rel. the
Regents of the University v. The Auditor-General, 17
Mich. 161 (1868), the Board of Regents of Michigan
University sued the Auditor-General to provide funds
to establish a school of homeopathy in the 1860s.10
Despite this early push for homeopathy, a little over
a century later a physician had his licence revoked by
a medical board for engaging in ‘unprofessional
conduct’ in prescribing homeopathic medicine in the
course of medical practice, which ‘departs from and
does not conform to the standards of acceptable and
prevailing medical practice in the State of North
Carolina.’11
Even though controlled clinical trials of homeopathic products have been contradictory, and key
concepts do not follow the laws of science, the debate
over these products continues.12 Nevertheless, the
FDA still has the responsibility to assure that all products placed on the market in the USA do not cross the
line of adulteration or misbranding. It appears that
the FDA is now reviewing these products with a more
critical eye.
The FDA’s enforcement against
homeopathy intensifies
In the last few years, the FDA has begun to flex its
enforcement muscle on homeopathic products by
focusing on adulteration and misbranding violations.
This enforcement is sometimes based on FDA tests of
homeopathic products. Recently, Terra-Medica (a US
company making homeopathic remedies) voluntarily
recalled more than 50 different products from across
its production line, based on tests conducted by the
FDA that showed these products contained penicillin.13 The obvious concern was that individuals who
were allergic to beta-lactam antibiotics, even at low
levels, could suffer a range of allergic reactions from
mild urticarial rashes to severe and life-threatening
anaphylactic reactions (including death).
It is clear from the above discussion that fraud and
misbranding are illegal activities in the USA. Does the
FDA take action against companies that commit
either or both of these transgressions? This depends
on the specific law being broken and the nature of
the transgressions.
The FDA’s warning letters
As mentioned above, the FDA routinely sends
warning letters to companies who are in violation
of the law. The agency warns the company about
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existing violations and demands an answer within a
few days that will address the violations and explain
the steps the company will take to remedy those
violation(s). On the surface, it would seem that
receiving such a letter would force any offending
company to immediately correct the illegal activity,
but is this the case?
The Hyland’s Teething Tablets tragedy
To explore the previous question, this paper will
provide an in-depth examination of FDA’s dealings
with one such company and the actions taken after
the FDA issued warning letters. The company to be
scrutinized is the Standard Homeopathic Company,
an institution behind a host of homeopathic products, including the Hyland’s product line. According
to its website, the company started in 1903, making
homeopathic products in a basement.14 It now
bills itself as the ‘only remaining American-owned
homeopathic company in the United States.’14
Standard Homeopathic has had several brushes
with the FDA. On October 3, 2010, the FDA issued a
news release and a consumer ‘question and answer’
explanation sheet describing a recently identified
problem with Hyland’s Teething Tablets.15,16 This
homeopathic product was, and still is, a nonprescription product intended to treat teething problems in children; it contains calcium phosphate,
chamomile, crude coffee and belladonna.17 The
company states that belladonna is present for
‘redness and teething discomfort.’17 One of the problems pointed out with this product by the FDA is
efficacy. In the words of the agency: ‘The FDA has not
evaluated Hyland’s Teething Tablets for safety or efficacy, and is not aware of any proven clinical benefit
offered by the product.’15 In other words, Standard
Homeopathic, by advertising the product for medical
uses that are not proven, appears to be committing
misbranding and health-fraud violations, as defined
by the FDA.
The second problem identified by the FDA with
these tablets is safety. The FDA mentioned in its news
release that, for dangerous ingredients such as the
belladonna in these teething tablets, the amount
must be carefully controlled to prevent harm and
death.15 Hyland’s should have taken every measure to
exercise that control.
In accordance with the unproven principles of
homeopathy (as described above), the active ingredients in these teething tablets are advertised as being
highly diluted. For instance, the concentration of
belladonna [i.e. Atropa belladonna (deadly nightshade)] is stated as ‘12X’ and the manufacturer currently calculates it as 0.0000000000003% alkaloids.17
With such extreme dilutions, Hyland’s Teething
Tablets and its other homeopathic products are composed mainly of water or milk sugar. At these
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supposed concentrations, the odds of finding a single
molecule of belladonna in an entire bottle of teething
tablets is remote. A purchaser is far more likely to win
the lottery than to purchase a bottle containing a
single molecule.
Thus, one would suppose that, at the very least,
Standard Homeopathic’s products would be manufactured under such controlled conditions that they
would pose no health risk due to belladonna.
However, Standard Homeopathic could not meet that
critical medical standard. For some unaccountable
reason, Standard Homeopathic’s substandard manufacturing practices allowed bottles of teething tablets
to reach the consumer marketplace containing toxic
amounts of belladonna.15,16 The FDA exposed
instances wherein children suffered ‘serious adverse
events’ consistent with belladonna toxicity. The
adverse reactions included seizures, difficulty breathing, lethargy, excessive sleepiness, muscle weakness,
skin flushing, constipation, difficulty urinating and
agitation; all of which followed ingestion of the toxic
Hyland’s Teething Tablets. Further, the products were
not marketed in child-resistant containers, allowing
children to consume more tablets than recommended and thus increasing the risk of injury and
death. The manufacturer issued a recall of the toxic
tablets, and the FDA recommended disposing of any
tablets remaining in the home. However, one can
conjecture that uncountable households did not
receive the warning, and the toxic tablets may still be
in medicine cabinets all over the USA, with wellintentioned parents waiting for the right time to give
them to a teething baby.
One of the authors (WSP) called the FDA to enquire
about the number of deaths and injuries owing to
Hyland’s Teething Tablets, but officials would not
provide any further information. Thus, the true
number of babies injured and killed by defective
homeopathic products in general, and by Hyland’s
Teething Tablets in particular, remains unknown.

In the 2011 letter, FDA also described misbranding
violations.18 The agency reviewed Standard Homeopathic’s labelling and website information for such
products as ‘Leg Cramps with Quinine Tablets’ and
‘Bedwetting Tablets.’ Standard Homeopathic advertised the former product for ‘Sciatica with pains in
tendons and ligaments.’ The latter product was said
to be useful for ‘incontinence with constant dribbling
in children,’ among other claims. The misbranding
issue will be discussed in more detail in the following
section.
The FDA’s 2013 health-fraud warning letter
to Standard Homeopathic
On September 19, 2013, the FDA sent a spate of letters to
companies marketing non-prescription products for
earache relief.19–23 Each letter was listed in the FDA’s files
as ‘Warning Letters – Health Fraud.’24 On September 25,
2013, a similar but much more extensive health-fraud
warning letter was sent by Alonza E Cruse of the FDA to
John P Borneman, Chief Executive Officer of the Standard Homeopathic Company, exposing false and misleading claims and misbranding.25
The letter to Borneman cited such earache relief
products as Hyland’s Earache Tablets, Earache Drops
and Infant Earache Drops. However, the FDA found a
large number of additional violations and also discovered numerous violations on the company’s websites. The additional investigative work required to
explore these illegalities may account for the 6-day
lag between other manufacturers’ warning letters and
the one sent to Standard Homeopathic. Among the
many Standard Homeopathic products cited as being
fraudulent were the following:
•

The FDA’s 2011 warning letter to
Standard Homeopathic
It appears that the teething tablet tragedy prompted
the FDA to look more closely at Standard Homeopathic’s operations in order to allow the agency to determine how to prevent future deaths and injuries. On
April 29, 2011, Alonza E Cruse, District Director of
the FDA, sent a warning letter to Mark S Phillips,
President of the Standard Homeopathic Company.18
The FDA acknowledged Standard Homeopathic’s
action to recall the toxic tablets. The FDA next
described the results of a 2010 inspection of the
firm’s Los Angeles facility, which uncovered significant violations of CGMP regulations. The FDA
inspectors listed numerous violations, some involving belladonna.
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•
•

•
•

Infant Earache Drops: the name indicated the
intended use for earaches. The company claimed
it temporarily relieves fever, pain, irritability and
sleeplessness associated with earaches in children,
after diagnosis by a physician, and relieves
common pain and itching of swimmer’s ear. Testimonials posted on Hyland’s website quoted one
writer as having relied on this product to treat
earache in an 8-month-old.
Hyland’s Teething Tablets were still (post-recall)
being advertised for helping reduce redness and
inflammation of the gums.
Hyland’s Vaginitis: the name indicated the
intended use. The product claimed to relieve
symptoms of vaginal itching and burning due to a
vaginal irritation or discharge after diagnosis by a
physician. Its ingredients include phenol and
creosote.
Hepar Sulphuris Calcareum: said to help localise
inflammation, as in bringing a boil to a head, and
to be of value in treating croup and laryngitis.
Hypericum perfoliatum: indicated for nerve injury.

Review
So, what was the basis for the misbranding violations
cited in the 2011 letter (e.g. bedwetting tablets) and
the numerous violations cited in this 2013 letter
(including the four examples listed above)? First, the
FDA explained that the Hyland’s products cited are
all defined as drugs in current law because (1) they
are intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans,
and (2) because they are intended to affect the structure or function of the body. The cited products are
all prescription medications within the law because
they are intended to treat diseases that require diagnosis and treatment by a physician or are intended to
provide treatment for symptoms usually caused by an
underlying disease process that requires diagnosis
and treatment by a physician. They are thus misbranded because Hyland’s did not place the symbol
‘Rx Only’ on the label.
The products are misbranded for another reason:
their labelling failed to bear adequate directions for
use as required by law. This deserves some explanation. First, the indications on the bottles are not
appropriate for over-the-counter (OTC) use. Second,
if indications such as those on Hyland’s labels require
the supervision of a licensed prescriber, adequate
directions for use cannot be written for any OTC
medication labelled for that indication. The products
were also found to be misbranded in that the labelling was false and misleading because it represented
the products as being suitable for use by consumers to
treat conditions that the FDA has found not appropriate for OTC drug treatment. Further, any customer
reviews on the website were evidence of the intended
uses of the products. Standard Homeopathic was
charged as being responsible for ensuring that
no statement causes any of their products to be
misbranded.
The FDA explained that the violations listed in the
letter were not all-inclusive, and Standard Homeopathic would be responsible for identifying and correcting all additional violations. Failure to promptly
correct all violations could result in legal action
without further notice, including, without limitation, seizure and injunction. Finally, the FDA gave
Standard Homeopathic 15 days from receipt of the
letter to notify the agency, in writing, of the specific
steps it would take to correct all violations.

One year later: status of violations
One year has passed since the September 2013
warning letter to Standard Homeopathic. A thorough
search of the FDA’s websites fails to provide any correspondence concerning this matter. Concerned
health professionals are justified in asking whether
these illegal, fraudulent products are still being
foisted on the American public.
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Unfortunately, as of the date of this writing, the
Hyland’s website retains the exact wording for at least
one product (Hyland’s Vaginitis) that was identified
as being illegal (e.g. the purported benefits to
‘Kreosotum’ and ‘Carbolicum Acidum’).26 Other
products have undergone minor modifications (e.g.
removal of the word ‘inflammation’). Some products
in violation (e.g. Hyland’s Vaginitis) have still not
been restricted to ‘Rx Only’ status.
The FDA’s response so far
An FDA official familiar with the case explained to
the authors that the Standard Homeopathic case is
ongoing. The company has responded, and the FDA
is evaluating those responses. The agency will
conduct another inspection to determine whether
the company has ceased illegal activity. Eventually,
the FDA will issue a close-out letter. However, this
case is still in ‘dialogue.’ The authors requested,
through the US Freedom of Information Act (FOIA),
all correspondence between the FDA and Standard
Homeopathic that bears on this issue. The authors
requested an expedited FOIA disclosure of all relevant
documents on the basis of an imminent health
hazard. The authors hope to publish a paper exploring this correspondence if the FDA is able to comply
with our FOIA request.
Conflict of interest None declared.
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